Abstract
Raloxifene augmentation in postmenopausal women with schizophrenia has shown promising results. Younger patients diagnosed as treatment-resistant schizophrenia and treated with raloxifene (120 mg/day) have reported significant improvement in symptoms. This case highlights how raloxifene, a selective estrogen receptor modulator (SERM), can play a major role in alleviating positive and negative symptoms in postmenopausal women with treatment-resistant schizophrenia.
This is a preview of subscription content, log in via an institution to check access.
References
Akhondzadeh S, Nejatisafa AA, Amini H et al (2003) Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 27(6):1007–1012
Kianimehr G, Fatehi F, Hashempoor S et al (2014) Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. DARU Journal of Pharmaceutical Sciences; 22(1):55. doi:10.1186/2008-2231-22-55
Kulkarni J, Riedel A, De Castella A et al (2001) Estrogen—a potential treatment for schizophrenia. Schizophr Res 48(1):137–144
Kulkarni J, De Castella A, Fitzgerald PB, Gurvich CT et al (2008) Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 65(8):955–60
Kulkarni J, Gurvich C, Lee SJ et al (2010) Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psycho neuroendocrinology 35(8):1142–1147
Kulkarni J, Gavrilidis E, Worsley R, Hayes E (2012) Role of estrogen treatment in the management of schizophrenia. CNS Drugs 26(7):549–557
Kulkarni J, Gavrilidis E, Wang W et al (2015) Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of childbearing age. Mol Psychiatry 20(6):695–702
Lindamer LA, BuseDC LJB et al (2001) Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 49(1):47–51
Usall J, Huerta-Ramos IR et al (2011) Raloxifene as adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, and placebo-controlled trial. J Clin Psychiatry 72(11):1552–1557
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tharoor, H., Goyal, A. Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia. Arch Womens Ment Health 18, 741–742 (2015). https://doi.org/10.1007/s00737-015-0545-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00737-015-0545-9